PanGenex (PGXC) Updates Following the Florida Chiropractic Association National Convention and Expo

Share Article

PanGenex Corporation (Pink Sheets:PGXC) hosted a successful product showcase at the Florida Chiropractic Association National Convention and Expo from August 22nd thru August 24th. PanGenex had the opportunity to directly meet over 500 practitioners from around the state of Florida and the rest of the country. In addition to the retail sales, PanGenex expects to realize new revenue as many of the practitioners have expressed interest in carrying LIPIDEMEâ„¢ and Omeganolâ„¢, core products of the PanGenex product line, which contain the purest Omega-3s available without a prescription and can be key elements in the battle against cholesterol and sudden cardiac arrest.

News Image

"Some of the most exciting aspects of the show were the opportunity to meet with several global distributors who requested product information for the sole purpose of nationwide distribution. I firmly expect to commence negotiations with multiple vendors that will move our product line distribution to the next level. The PanGenex product line gives practitioners the ability to offer pharmaceutical grade product solutions with tremendous wellness benefits," states Jeff Roman, President and CEO of PanGenex.

About PanGenex Corporation:

PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products. Each product is scientifically formulated to address specific health conditions. Many of our products contain the purest grade of nutraceutical components available anywhere without a prescription. PanGenex markets products through healthcare practitioners, retail establishments and the internet on websites such as, and .



This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. The statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Roman
Visit website